The latest installment of Qazi Corner is here! The sixth edition of our collaborative quarterly #gastroenterology newsletter features a trio of articles from Cleveland Clinic experts and interviews with editor-in-chief Taha Qazi. Check out his intro here: hcplive.com/view/qazi-corn…

Setting up my interview spot here at #RAD2024 above the conference area. I feel so lucky that I get to attend these #dermatology conferences and speak to the clinicians whose names I see on all the studies I cover. Check out our latest coverage: hcplive.com/conference/rev…

BREAKING: The FDA has approved elfibranor (Iqirvo; @IpsenGroup) for the treatment of primary biliary cholangitis in combination with UDCA in adults w/ an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. hcplive.com/view/fda-grant… #Hepatology

JAK inhibitors have revolutionized #dermatology. What comes next? Perhaps greater combination care between the targeted agents and older therapies. Watch the interview segment with Dr. Zirwas: hcplive.com/view/potential… #DermTwitter #Alopecia #Vitiligo #HidradenitisSuppurativa

Greatest baseball player ever

Feels like there's been a metric ton of development in #cholestatic disease care in only the last 12 months—and yet there's even more room for growth. Check out our latest Special Report on developments in #PBC at the link ⬇️⬇️⬇️

Last-minute packing for #ADA24 and then off to Orlando! Super excited to see new data on tirzepatide, inhaled insulin, the CATALYST trial, and more this weekend! Follow on HCPLive for the latest updates! hcplive.com/conference/ada

New #Lungcast! Avrum Spira, MD of Boston U Chobanian & Avedisian School of Medicine and Steven Dubinett, MD of David Geffen School of Medicine at UCLA return to the show to give an update on their research into #LungCancer interception. Watch the episode here: hcplive.com/view/stopping-… American Lung Association LUNGevity Foundation

Breaking tonight: The #FDA has approved ensifentrine (Ohtuvayre), from Verona Pharma, for the treatment of patients with #COPD. Read more about the new indication and its supporting data here: hcplive.com/view/fda-appro…

Exclusive coverage 🔒: Our rundown of 7 highly anticipated #FDA decisions for the rest of 2024. Here's a spoiler from the first decision: vonoprazan for non-erosive #GERD. Sign up to read / listen about the other 6: hcplive.com/view/7-fda-dru…

Had another opportunity to interview Raj Chovatiya, MD PhD on his team's findings on the prevalence of #SeborrheicDermatitis. Dr. Chovatiya's interviews with HCPLive are always a highlight of our #dermatology coverage. Informative as always! Check it out here: hcplive.com/view/discussin…

WARDELL

New #Lungcast! For Back to School, the American Lung Association spoke with Juanita Mora, MD and Christy Sadreameli or @pedlungdoc on bsky on a number of pediatric respiratory health topics—#RSV risk, vaping, and the dreaded #Asthma Peak Week. Watch / listen to the full episode here: hcplive.com/view/back-to-s…

I'm heading to Copenhagen for #ECTRIMS2024 in a couple of weeks for NeurologyLive®. It's always one of my favorite meetings, and the program is (once again) stacked this year. Let me know if you're presenting there and would like to chat about your work (or just say hi)!

Today's #AdComm meeting is coming close to an end—our colleague Hannah Clarke has created a truly robust live journal of the daylong deliberations. Catch up on the discussion around the #sulopenem FDA application for UTIs at the link before the big vote! #IDTwitter #UroTwitter

BREAKING: The US FDA has announced the approval xanomeline and trospium chloride capsules (Cobenfy), for #schizophrenia. hcplive.com/view/fda-appro…

Train-bound for my first ever ASTRO meeting! Excited to get into all the new updates in prostate cancer and more for Urology Times. Hope you follow along! #ASTRO24

In their new Forefront article, Kathleen Noonan + Mary D. Naylor from Camden Coalition + Penn discuss how, as our nation ages, it is time to design new place-based care models that capitalize on the strengths of our old-style institutional care and current approaches to